Publications
Selected publications
Targeting mitochondria in cancer therapy could provide a basis for the selective anti-cancer activity.
Rozanov D, Cheltsov A, Nilsen A, Boniface C, Forquer I, Korkola J, Gray J, Tyner J, Tognon CE, Mills GB, Spellman P.
PloS one. 2019; 14(3):e0205623. PubMed [journal]. PMID: 30908483.
Predicting response to BET inhibitors using computational modeling: A BEAT AML project study.
Drusbosky LM, Vidva R, Gera S, Lakshminarayana AV, Shyamasundar VP, Agrawal AK, Talawdekar A, Abbasi T, Vali S, Tognon CE, Kurtz SE, Tyner JW, McWeeney SK, Druker BJ, Cogle CR.
Leukemia research. 2019; 77:42-50. PubMed [journal]. PMID: 30642575.
LMTK3 is essential for oncogenic KIT expression in KIT-mutant GIST and melanoma.
Klug LR, Bannon AE, Javidi-Sharifi N, Town A, Fleming WH, VanSlyke JK, Musil LS, Fletcher JA, Tyner JW, Heinrich MC.
Oncogene. 2019; 38(8):1200-1210. NIHMSID: NIHMS1505443. PubMed [journal]. PMID: 30242244 PMCID: PMC6365197.
ARID1A and CEBPα cooperatively inhibit UCA1 transcription in breast cancer.
Guo X, Zhang Y, Mayakonda A, Madan V, Ding LW, Lin LH, Zia S, Gery S, Tyner JW, Zhou W, Yin D, Lin DC, Koeffler HP.
Oncogene. 2018; 37(45):5939-5951. PubMed [journal]. PMID: 29980791.
Functional genomic landscape of acute myeloid leukaemia.
Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, Long N, Schultz AR, Traer E, Abel M, Agarwal A, Blucher A, Borate U, Bryant J, Burke R, Carlos A, Carpenter R, Carroll J, Chang BH, Coblentz C, d'Almeida A, Cook R, Danilov A, Dao KT, Degnin M, Devine D, Dibb J, Edwards DK 5th, Eide CA, English I, Glover J, Henson R, Ho H, Jemal A, Johnson K, Johnson R, Junio B, Kaempf A, Leonard J, Lin C, Liu SQ, Lo P, Loriaux MM, Luty S, Macey T, MacManiman J, Martinez J, Mori M, Nelson D, Nichols C, Peters J, Ramsdill J, Rofelty A, Schuff R, Searles R, Segerdell E, Smith RL, Spurgeon SE, Sweeney T, Thapa A, Visser C, Wagner J, Watanabe-Smith K, Werth K, Wolf J, White L, Yates A, Zhang H, Cogle CR, Collins RH, Connolly DC, Deininger MW, Drusbosky L, Hourigan CS, Jordan CT, Kropf P, Lin TL, Martinez ME, Medeiros BC, Pallapati RR, Pollyea DA, Swords RT, Watts JM, Weir SJ, Wiest DL, Winters RM, McWeeney SK, Druker BJ.
Nature. 2018; 562(7728):526-531. NIHMSID: NIHMS1504008. PubMed [journal]. PMID: 30333627 PMCID: PMC6280667.
Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia.
Kurtz SE, Eide CA, Kaempf A, Mori M, Tognon CE, Borate U, Druker BJ, Tyner JW.
Leukemia. 2018; 32(9):2025-2028. NIHMSID: NIHMS989869. PubMed [journal]. PMID: 30082821 PMCID: PMC6168939.
Automated decision tree to evaluate genetic abnormalities when determining prognostic risk in acute myeloid leukemia.
Watanabe-Smith K, Druker BJ, Tyner JW, Edwards DK 5th.
Haematologica. 2018; 103(8):e351-e355. PubMed [journal]. PMID: 29567769. PMCID: PMC6068037.
Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples.
Edwards V DK, Sweeney DT, Ho H, Eide CA, Rofelty A, Agarwal A, Liu SQ, Danilov AV, Lee P, Chantry D, McWeeney SK, Druker BJ, Tyner JW, Spurgeon SE, Loriaux MM.
Oncotarget. 2018; 9(37):24576-24589. PubMed [journal]. PMID: 29872489. PMCID: PMC5973855.
Super-Enhancers Promote Transcriptional Dysregulation in Nasopharyngeal Carcinoma.
Yuan J, Jiang YY, Mayakonda A, Huang M, Ding LW, Lin H, Yu F, Lu Y, Loh TKS, Chow M, Savage S, Tyner JW, Lin DC, Koeffler HP.
Cancer research. 2017; 77(23):6614-6626. PubMed [journal]. PMID: 28951465.
EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT.
Merchant AA, Jorapur A, McManus A, Liu R, Krasnoperov V, Chaudhry P, Singh M, Harton L, Agajanian M, Kim M, Triche TJ Jr, Druker BJ, Tyner JW, Gill PS.
Blood advances. 2017; 1(20):1635-1644. PubMed [journal]. PMID: 29296810. PMCID: PMC5728330.
Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.
Kurtz SE, Eide CA, Kaempf A, Khanna V, Savage SL, Rofelty A, English I, Ho H, Pandya R, Bolosky WJ, Poon H, Deininger MW, Collins R, Swords RT, Watts J, Pollyea DA, Medeiros BC, Traer E, Tognon CE, Mori M, Druker BJ, Tyner JW.
Proceedings of the National Academy of Sciences of the United States of America. 2017; 114(36):E7554-E7563. PubMed [journal]. PMID: 28784769. PMCID: PMC5594650.
Recurrent cyclin D2 mutations in myeloid neoplasms.
Khanna V, Eide CA, Tognon CE, Maxson JE, Wilmot B, Bottomly D, McWeeney S, Edwards V DK, Druker BJ, Tyner JW.
Leukemia. 2017; 31(9):2005-2008. NIHMSID: NIHMS932435. PubMed [journal]. PMID: 28630439. PMCID: PMC5763909.